Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)

Launched by MINGZHAO XIAO · Oct 12, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to predict how long patients with localized clear cell renal cell carcinoma (ccRCC) might remain free from disease after surgery. Researchers are using advanced computer technology, called a deep learning model, which analyzes special CT scan images enhanced with contrast dye to make these predictions. The goal is to see if this new method can provide accurate predictions and how it compares to traditional models that doctors currently use.

To participate in this trial, individuals must have had surgery to remove part or all of their kidney due to ccRCC and have clear medical records along with pre-surgery CT scan images. However, patients who have incomplete medical information, poor-quality CT images, or who have received other treatments before surgery are not eligible. If you join this study, you can expect to contribute to important research that could help improve predictions for future patients with this type of kidney cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • underwent partial/radical nephrectomies
• • histologically diagnosed as ccRCC
• • with complete clinical data and preoperative CT image data
• Exclusion Criteria:
• • with incomplete clinic-pathological data
• • lack of preoperative contrast-enhanced CT images or the image quality was unsuitable for analysis
• • who received pre-surgery neoadjuvant or adjuvant therapies
• • with multiple renal tumors or/and had synchronous metastasis